| Assessment Status |
Awaiting response from Applicant |
| HTA ID |
21049 |
| Drug |
Nivolumab |
| Brand |
Opdivo® |
| Indication |
Nivolumab is indicated in combination with fluoropyrimidine and platinum-based combination chemotherapy for the first line treatment of adult patients with HER2 negative advanced or metastatic gastric, gastro oesophageal junction or oesophageal adenocarcinoma whose tumours express PD-L1 with a combined positive score (CPS) ≥5. |
| Rapid review commissioned |
01/11/2021 |
| Rapid review completed |
29/11/2021 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of nivolumab compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
07/12/2021 |
| Pre-submission consultation with Applicant |
01/02/2022 |
| Full submission received from Applicant |
10/10/2022 |
| Preliminary review sent to Applicant |
27/03/2023 |
